F
Fang Lou
Researcher at Sir Run Run Shaw Hospital
Publications - 11
Citations - 1301
Fang Lou is an academic researcher from Sir Run Run Shaw Hospital. The author has contributed to research in topics: Autophagy & Cancer. The author has an hindex of 8, co-authored 11 publications receiving 1075 citations.
Papers
More filters
Journal ArticleDOI
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment
Xinbing Sui,R Chen,Z Wang,Z Huang,Na Kong,M Zhang,Weidong Han,Fang Lou,Jing Yang,Qian Zhang,Xian Wang,Chao He,Hongming Pan +12 more
TL;DR: Understanding the novel function of autophagy may allow us to develop a promising therapeutic strategy to enhance the effects of chemotherapy and improve clinical outcomes in the treatment of cancer patients.
Journal ArticleDOI
JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy
Xinbing Sui,Na Kong,Xian Wang,Yong Fang,Xiaotong Hu,Yinghua Xu,Wei Chen,Kaifeng Wang,Da Li,Wei Jin,Fang Lou,Yu Zheng,Hong Hu,Liu Gong,Xiaoyun Zhou,Hongming Pan,Weidong Han +16 more
TL;DR: The results suggest that JNK activation confers 5-FU resistance in HCT116 p53−/− and HT29 cells by promoting autophagy as a pro-survival effect, likely via inducing Bcl-2 phosphorylation.
Journal ArticleDOI
Autophagy-associated immune responses and cancer immunotherapy
Hongming Pan,Liuxi Chen,Yinghua Xu,Weidong Han,Fang Lou,Weiqiang Fei,Shuiping Liu,Zhao Jing,Xinbing Sui +8 more
TL;DR: The role of autophagy in immune regulation is described, the possible molecular mechanisms that are currently well documented in the ability of autophileagy to control cell immune response are summarized, and the scientific and clinical hurdles regarding the potential role of Autophileagy in cancer immunotherapy are discussed.
Journal ArticleDOI
Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China
Chongya Zhai,Yulan Cai,Fang Lou,Zhen Liu,Jiansheng Xie,Xiaoyun Zhou,Zhanggui Wang,Yong Fang,Hongming Pan,Weidong Han +9 more
TL;DR: The early diagnosis of rare MPMTs should not be neglected in patients not only when treated for a primary malignancy but also during long-term follow-up, and effective treatment for MP MTs may yield promising curative effect and warrants further investigation.
Journal ArticleDOI
Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation.
Xinbing Sui,Yinghua Xu,Jie Yang,Yong Fang,Haizhou Lou,Weidong Han,Maolin Zhang,Wei Chen,Kaifeng Wang,Da Li,Wei Jin,Fang Lou,Yu Zheng,Hong Hu,Liu Gong,Xiaoyun Zhou,Qin Pan,Hongming Pan,Xian Wang,Chao He +19 more
TL;DR: It is suggested that metformin has not antineoplastic activity for CRC cells as a single agent but AMPK activator AICAR can induce apoptosis and enhance the cytotoxic effect of 5-FU through AMPK activation.